Cocrystal Pharma
COCP
41 hedge funds and large institutions have $16.1M invested in Cocrystal Pharma in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
0.4% less ownership
Funds ownership: 1.71% → 1.31% (-0.4%)
2% less funds holding
Funds holding: 42 → 41 (-1)
36% less capital invested
Capital invested by funds: $25M → $16.1M (-$8.94M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$267K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$203K |
| 3 |
Millennium Management
New York
|
+$150K |
| 4 |
Mariner
Overland Park,
Kansas
|
+$110K |
| 5 |
Two Sigma Advisers
New York
|
+$63.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.44M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.04M |
| 3 |
ACM
Altium Capital Management
New York
|
-$970K |
| 4 |
Renaissance Technologies
New York
|
-$625K |
| 5 |
Squarepoint
New York
|
-$242K |
COCP Hedge Fund Activity: Q3 2021 in Review
41 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q3 2021, worth a combined $16.1M — down 36% from $25M a quarter earlier.
Fund positioning in COCP was balanced in Q3 2021: 6 funds opened new positions, 6 closed out, 11 added to existing stakes and 11 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $267K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $3.44M sold.
- 41 institutional investors held Cocrystal Pharma (COCP) as of Q3 2021, down from 42 in Q2 2021.
- Funds reported $16.1M of Cocrystal Pharma stock for Q3 2021, down 36% quarter-over-quarter.
- 6 funds opened new Cocrystal Pharma positions in Q3 2021 and 6 closed out, a net change of 0 holders.
- The largest Cocrystal Pharma buyer in Q3 2021 was Geode Capital Management, an estimated $267K added.
- The largest Cocrystal Pharma seller in Q3 2021 was Alyeska Investment Group, an estimated $3.44M sold.
Based on aggregated 13F filings for Q3 2021.